Patents Assigned to The Feinstein Institute for Medical Research
-
Publication number: 20110236406Abstract: The present invention relates to novel immunogenic compositions (e.g., vaccines), the production of such immunogenic compositions and methods of using such compositions. More specifically, this invention provides unique immunogenic molecules comprising an HMGB1 polypeptide (e.g., an HMGB1 B-box polypeptide) and an antigen. Even more specifically, this invention provides novel fusion proteins comprising an isolated HMGB1 polypeptide and an antigen such that administration of these fusion proteins provides the two signals required for native T-cell activation.Type: ApplicationFiled: January 18, 2011Publication date: September 29, 2011Applicants: MedImmune, LLC, The Feinstein Institute for Medical ResearchInventors: Davorka Messmer, Kevin Tracey, Peter Kiener, Scott Alban
-
Patent number: 8003632Abstract: A method of treating a subject with a cytokine-mediated inflammatory disorder comprising administering to the subject an effective amount of a pharmaceutically acceptable cholinesterase inhibitor, provided that the inhibitor is not galantamine.Type: GrantFiled: August 14, 2007Date of Patent: August 23, 2011Assignee: The Feinstein Institute for Medical ResearchInventors: Kevin J. Tracey, Valentin A. Pavlov
-
Publication number: 20110166148Abstract: A method of treating a patient suffering from pancreatitis comprising treating said patient with a therapeutically effective amount of a cholinergic agonist selective for an ?7 nicotinic receptor in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from a macrophage wherein said condition is acute pancreatitis. The compounds of the present invention include a quaternary analog of cocaine; (1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid 1-(2-fluorophenyl)-ethyl ester; a compound of formula (I), a compound of formula (II), a compound of formula (III), a compound of formula (IV), and an oligonucleotide or mimetic capable of attenuating the symptoms of acute pancreatitis wherein the oligonucleotide or mimetic consists essentially of a sequence greater than 5 nucleotides long that is complementary to an mRNA of an ?7 cholinergic receptor. The variables of formulae (I), (II), (III) and (IV) are described herein.Type: ApplicationFiled: March 16, 2010Publication date: July 7, 2011Applicant: The Feinstein Institute for Medical ResearchInventors: Kevin J. Tracey, Hong Wang
-
Publication number: 20110136911Abstract: Methods and compositions are disclosed for the use of dextrothyroxine (D-T4) to treat sepsis, inflammation, and conditions and diseases in which it is desirable to inhibit macrophage migration inhibitory factor (MIF).Type: ApplicationFiled: December 18, 2008Publication date: June 9, 2011Applicant: The Feinstein Institute for Medical ResearchInventor: Yousef Al-Abed
-
Publication number: 20110091867Abstract: The present invention provides a method for distinguishing benign human papilloma virus (HPV)-infected tissue from HPV-related lesions that have undergone malignant transformation. In one embodiment, the invention comprises a simple histochemical staining method and details a novel process for examining HPV-infected cells by determining susceptibility to enzymatic DNA digestion. Residual virion-associated DNA is seen only in benign HPV-infected lesions, while absence of residual DNA is seen with malignant transformation. In another embodiment, the invention comprises immunohistochemical assay methods for examining HPV-infected cells, utilizing antibodies to HPV L1 proteins. These methods can be used to predict biologic behavior of HPV-infected lesions. The invention can improve current cervical cancer screening programs, and improve clinical management of patients by defining malignant potential of HPV-infected tissue more accurately.Type: ApplicationFiled: December 20, 2010Publication date: April 21, 2011Applicants: STATEN ISLAND UNIVERSITY, THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCHInventor: Mario R. CASTELLANOS
-
Patent number: 7910299Abstract: The invention relates to methods and materials involved in diagnosing SLE. More particularly, the invention relates to methods and materials involved in diagnosing SLE, diagnosing severe SLE, and assessing a mammal's susceptibility to develop severe SLE. For example, the invention provides nucleic acid arrays that can be used to diagnose SLE in a mammal. Such arrays can allow clinicians to diagnose SLE based on a simultaneous determination of the expression levels of many genes that are differentially expressed in SLE patients as compared to healthy controls.Type: GrantFiled: October 3, 2006Date of Patent: March 22, 2011Assignees: Regents of the University of Minnesota, The Feinstein Institute for Medical ResearchInventors: Timothy W. Behrens, Emily C. Baechler, Peter K. Gregersen
-
Patent number: 7897569Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.Type: GrantFiled: September 19, 2007Date of Patent: March 1, 2011Assignees: The Feinstein Institute for Medical Research, The General Hospital Corporation, University of Pittsburgh of the Commonwealth System of Higher EducationInventors: Kevin J. Tracey, Huan Yang, Howland Shaw Warren, Jr., Mitchell P. Fink
-
Publication number: 20100303813Abstract: The present disclosure provides biomarkers that are predictive a subject's responsiveness or non-responsiveness to an anti-TNF therapy. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities (e.g., an anti-TNF therapy or a non-anti-TNF therapy) for a subject suffering from a disease such as an immune disorder.Type: ApplicationFiled: June 6, 2008Publication date: December 2, 2010Applicants: Biogen Idec MA Inc., The Feinstein Institute for Medical ResearchInventors: John P. Carulli, Peter K. Gregersen, Franak Batliwalla, Jadwiga Bienkowska, Chunyu Liu
-
Patent number: 7842461Abstract: The subject invention discloses a method for determining the prognosis and probable clinical course of a subject diagnosed with B-CLL. Specifically, the invention involves comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein an elevated level of CD38 expression in relation to the baseline level of CD38 expression may indicate poor prognosis or aggressive course of disease in the subject. Also disclosed is a method for determining whether the Ig V genes of the B-CLL cells of a B-CLL patient are mutated, comprising comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein a lower level of CD38 expression in relation to the baseline level indicates IG V gene mutation.Type: GrantFiled: April 26, 2007Date of Patent: November 30, 2010Assignee: The Feinstein Institute for Medical ResearchInventors: Nicholas Chiorazzi, Rajendra N. Damle, Tarun Wasil
-
Publication number: 20100285455Abstract: Provided are methods of identifying a genetic profile influencing the relative probability of a subject manifesting a phenotype that is at least partially heritable. Also provided are methods of determining the relative likelihood that a subject will manifest a phenotype that is at least partially heritable. Additionally, methods of determining the relative risk of a human subject for manifesting schizophrenia are provided. Further provided are methods of screening a human embryo in vitro for the risk of becoming a human manifesting schizophrenia. Also, methods of identifying a single nucleotide polymorphism (SNP) variant affecting the risk of a human subject for manifesting schizophrenia are provided. Methods of screening for a compound that may affect schizophrenia are additionally provided.Type: ApplicationFiled: June 10, 2008Publication date: November 11, 2010Applicant: THE FEINSTEIN INSTITUTE MEDICAL RESEARCHInventors: Todd Lencz, Anil K. Malhotra, John m. Kane
-
Patent number: 7829097Abstract: Methods and compositions are disclosed for protecting an organ or tissue from inflammation and organ injury following ischemia, reperfusion, and trauma through the administration of an HMGB1 protein within a time period sufficient to protect the organ or tissue from injury.Type: GrantFiled: February 6, 2007Date of Patent: November 9, 2010Assignees: University of Pittsburgh - Of the Commonwealth System of Higher Education, The Feinstein Institute for Medical ResearchInventors: Allan Tsung, Timothy R. Billiar, Mitchell P. Fink, Kevin J. Tracey
-
Patent number: 7807696Abstract: Compounds of Formula (I), pharmaceutical compositions comprising compounds of Formulae (I a) or (VII) and a method of treating a subject with an inflammatory cytokine-mediated disorder comprising administering to the subject a compound of Formulae (I a) or (VII a). The variables of Formulae (I), (I a), (VII) and (VII a) are described herein.Type: GrantFiled: October 7, 2004Date of Patent: October 5, 2010Assignee: The Feinstein Institute for Medical ResearchInventors: Yousef Al-Abed, Kevin J. Tracey
-
Patent number: 7785808Abstract: A method of treating a patient suffering from pancreatitis comprising treating said patient with a therapeutically effective amount of a cholinergic agonist selective for an ?7 nicotinic receptor in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from a macrophage wherein said condition is acute pancreatitis. The compounds of the present invention include a quaternary analog of cocaine; (1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid 1-(2-fluorophenyl)-ethyl ester; a compound of formula (I), a compound of formula (II), a compound of formula (III), a compound of formula (IV), and an oligonucleotide or mimetic capable of attenuating the symptoms of acute pancreatitis wherein the oligonucleotide or mimetic consists essentially of a sequence greater than 5 nucleotides long that is complementary to an mRNA of an ?7 cholinergic receptor. The variables of formulae (I), (II), (III) and (IV) are described herein.Type: GrantFiled: March 15, 2007Date of Patent: August 31, 2010Assignee: The Feinstein Institute for Medical ResearchInventors: Kevin J. Tracey, Hong Wang
-
Publication number: 20100172905Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk of exhibiting sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.Type: ApplicationFiled: July 1, 2009Publication date: July 8, 2010Applicant: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCHInventors: KEVIN J. TRACEY, HAICHAO WANG
-
Patent number: 7749959Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.Type: GrantFiled: September 19, 2007Date of Patent: July 6, 2010Assignees: The Feinstein Institute for Medical Research, The General Hospital Corporation, University of Pittsburgh-of the Commonwealth System of Higher EducationInventors: Kevin J. Tracey, Huan Yang, Howland Shaw Warren, Jr., Mitchell P. Fink
-
Patent number: 7696169Abstract: The invention features a method of treating an inflammatory condition in an individual, comprising administering an agent inhibits the interaction between a Toll-like receptor 2 (TLR2) and a high mobility group B (HMGB) polypeptide to the individual. The invention also features methods for identifying agents that inhibit the interaction between TLR2 and HMGB.Type: GrantFiled: April 13, 2007Date of Patent: April 13, 2010Assignee: The Feinstein Institute for Medical ResearchInventors: Kevin J. Tracey, Huan Yang
-
Publication number: 20090324588Abstract: An antibody or an antigen binding fragment thereof which binds to mammalian ?7 subunit of a nicotinic acetylcholine receptor or its functional variant and which is an agonist of said receptor or variant. Pharmaceutical compositions comprising same. A method of treating a subject suffering from an inflammatory condition comprising administering to said subject an antibody or an antigen-binding fragment as described herein.Type: ApplicationFiled: November 15, 2006Publication date: December 31, 2009Applicant: The Feinstein Institute for Medical ResearchInventors: Lihong Yang, Kevin J. Tracey
-
Publication number: 20090248097Abstract: A method of inhibiting the release of a proinflammatory cytokine in a cell is disclosed. The method comprises treating the cell with a cholinergic agonist. The method is useful in patients at risk for, or suffering from, a condition mediated by an inflammatory cytokine cascade, for example endotoxic shock. The cholinergic agonist treatment can be effected by stimulation of an efferent vagus nerve fiber, or the entire vagus nerve.Type: ApplicationFiled: April 24, 2008Publication date: October 1, 2009Applicant: Feinstein Institute for Medical Research, TheInventors: Kevin J. Tracey, Jared M. Huston
-
Patent number: 7572446Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk of exhibiting sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.Type: GrantFiled: June 29, 2006Date of Patent: August 11, 2009Assignee: The Feinstein Institute for Medical ResearchInventors: Kevin J. Tracey, Haichao Wang
-
Patent number: 7571055Abstract: This document relates to methods and materials involved in diagnosing SLE. For example, this document relates to methods and materials involved in diagnosing SLE, diagnosing severe SLE, and assessing a mammal's susceptibility to develop severe SLE. For example, this document provides nucleic acid arrays that can be used to diagnose SLE in a mammal. Such arrays can allow clinicians to diagnose SLE based on a simultaneous determination of the expression levels of many genes that are differentially expressed in SLE patients as compared to healthy controls. In addition, methods and materials for assessing SLE activity, determining the likelihood of experiencing active SLE, and detecting SLE treatment effectiveness are provided herein.Type: GrantFiled: October 13, 2005Date of Patent: August 4, 2009Assignees: Regents of the University of Minnesota, The Feinstein Institute for Medical ResearchInventors: Timothy W. Behrens, Emily C. Gillespie, Peter K. Gregersen